We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

41 hedge funds and large institutions have $225M invested in Spruce Biosciences in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

3% more funds holding

Funds holding: 40 → 41 (+1)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

28% less capital invested

Capital invested by funds: $313M → $225M (-$87.9M)

Holders
41
Holders Change
+1
Holders Change %
+2.5%
% of All Funds
0.71%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
5
Increased
17
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$29.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.58M
3
CCM
CAAS Capital Management
New York
+$1.31M
4
Morgan Stanley
Morgan Stanley
New York
+$1.26M
5
BlackRock
BlackRock
New York
+$1.06M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$8.13M
2
NHAS
Novo Holdings A/S
Denmark
-$6.76M
3
SCM
Sio Capital Management
New York
-$2.36M
4
ACH
ArrowMark Colorado Holdings
Colorado
-$2.13M
5
Millennium Management
Millennium Management
New York
-$794K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$50.6M -$6.76M -6,333 -10%
OFM
2
Omega Fund Management
Massachusetts
$24.2M – – –
RVM
3
RiverVest Venture Management
Missouri
$24.1M – – –
DM
4
Deerfield Management
New York
$22.9M +$29.1M +27,293 New
Citadel Advisors
5
Citadel Advisors
Florida
$19.1M +$3.2K +3 +0%
RSCM
6
Rock Springs Capital Management
Maryland
$18M +$366K +343 +2%
ACM
7
Aisling Capital Management
New York
$13.5M – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$13.3M -$134K -126 -0.8%
Sands Capital Management
9
Sands Capital Management
Virginia
$8.82M – – –
SCM
10
Sio Capital Management
New York
$7.26M -$2.36M -2,208 -20%
BlackRock
11
BlackRock
New York
$4.71M +$1.06M +993 +22%
Vanguard Group
12
Vanguard Group
Pennsylvania
$4.14M +$2.58M +2,413 +96%
Adage Capital Partners
13
Adage Capital Partners
Massachusetts
$2.7M -$711K -666 -17%
JP Morgan Chase
14
JP Morgan Chase
New York
$1.84M -$229K -215 -9%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.44M +$270K +253 +17%
State Street
16
State Street
Massachusetts
$1.4M +$430K +403 +32%
Morgan Stanley
17
Morgan Stanley
New York
$1.38M +$1.26M +1,178 +258%
GPCM
18
Granite Point Capital Management
Massachusetts
$1.12M – – –
CCM
19
CAAS Capital Management
New York
$1.04M +$1.31M +1,232 New
Northern Trust
20
Northern Trust
Illinois
$873K +$24.5K +23 +2%
Charles Schwab
21
Charles Schwab
California
$485K -$13.9K -13 -2%
AA
22
ALPS Advisors
Colorado
$344K +$438K +410 New
Nuveen
23
Nuveen
North Carolina
$332K +$259K +243 +160%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$286K +$90.7K +85 +33%
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
$218K +$276K +259 New
1
2

SPRB Hedge Fund Activity: Q2 2021 in Review

41 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2021, worth a combined $225M — down 28% from $313M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SPRB positions and 4 closed out — a net gain of 1 holder — while 17 added to existing stakes and 11 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $29.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $8.13M sold.

  • 41 institutional investors held Spruce Biosciences (SPRB) as of Q2 2021, up from 40 in Q1 2021.
  • Funds reported $225M of Spruce Biosciences stock for Q2 2021, down 28% quarter-over-quarter.
  • 5 funds opened new Spruce Biosciences positions in Q2 2021 and 4 closed out, a net change of +1 holder.
  • The largest Spruce Biosciences buyer in Q2 2021 was Deerfield Management, an estimated $29.1M added.
  • The largest Spruce Biosciences seller in Q2 2021 was PFM Health Sciences, an estimated $8.13M sold.

Based on aggregated 13F filings for Q2 2021.